Pyxis Oncology Inc
General ticker "PYXS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $105.4M
Pyxis Oncology Inc does not follow the US Stock Market performance with the rate: -3.9%.
Estimated limits based on current volatility of 2.1%: low 1.54$, high 1.69$
Factors to consider:
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.10$, 2.98$]
- 2024-12-30 to 2025-12-30 estimated range: [1.30$, 3.34$]
Financial Metrics affecting the PYXS estimates:
- Negative: Non-GAAP EPS, $ of -1.84 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -50.84 <= 2.35
- Negative: negative Net income
- Positive: Inventory ratio change, % of -200 <= -1.03
- Positive: -3.48 < Investing cash flow per share, $ of -2.63
Short-term PYXS quotes
Long-term PYXS plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
Operating Expenses | $69.72MM | $123.48MM | $82.20MM |
Operating Income | $-69.72MM | $-123.48MM | $-82.20MM |
Non-Operating Income | $-6.26MM | $2.76MM | $8.41MM |
R&D Expense | $51.05MM | $86.13MM | $49.59MM |
Income(Loss) | $-75.97MM | $-120.72MM | $-73.79MM |
Profit(Loss) | $-75.97MM | $-120.72MM | $-73.79MM |
Stockholders Equity | $261.31MM | $160.82MM | $125.70MM |
Inventory | $0.00MM | $0.87MM | $0.00MM |
Assets | $280.02MM | $211.38MM | $173.73MM |
Operating Cash Flow | $-35.33MM | $-89.33MM | $-70.71MM |
Capital expenditure | $0.54MM | $6.40MM | $6.73MM |
Investing Cash Flow | $-0.59MM | $-6.40MM | $-104.85MM |
Financing Cash Flow | $304.04MM | $0.18MM | $5.93MM |
Earnings Per Share* | $-2.53 | $-3.57 | $-1.85 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.